



PRESS RELEASE

Eurocor: Convincing initial results in the DIOR Debiut study

Bonn, 25. June 2010 – What is the long-term efficacy and efficiency of treating bifurcation stenosis with the Drug Eluting Balloon (DEB) DIOR? This is examined by the so-called Debiut study. DIOR is a drug releasing heart catheter by the Bonn life sciences company **Eurocor GmbH** that has been specially developed for treating bifurcated vessels (bifurcation stenosis). The innovative approach permits drug-supported treatment of the arteries with special focus on the side branch without a stent.

The Debiut study also looks at how effective a drug-coated balloon (DEB) is compared to a non drug-coated balloon.

Even though the study will be running through to autumn 2014, initial important results are already emerging. It transpires that the combination of DIOR and BMS in the main branch and DIOR in the side branch offers a particularly efficient method for treating bifurcation, particularly in view of restenosis in the blood vessel.

The method is also very safe. None of the patients developed thrombosis. This also confirms that anticoagulant drugs only have to be administered for a three-month period in the case of DEB treatment.



The results of the multicentre study (Utrecht, Holland; Genk, Belgium; Leuven, Belgium; Essen, Germany) were presented by Dr. Pieter Stella, clinical study leader, at the EuroPCR 2010 in Paris.

"Since we launched the first of these so-called DEBs more than two years ago, Eurocor has become the undisputed technology leader on this segment. This is also confirmed impressively by the latest study", says Katja Hausner, Director Corporate Business Affairs at Eurocor.

The company

Eurocor GmbH is a rapidly growing life sciences company specialising in the research, development and manufacture of cardiovascular catheter devices and coronary stent technologies. The products manufactured by the company in Bonn are used in minimally invasive cardiovascular surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Eurocor has developed an innovative method for drug-eluting balloon catheters with maximum patient safety and compatibility.

Become a follower of http://twitter.com/Eurocor_Germany

You can also find Eurocor on Facebook. Become a fan.

Press contact:

Blattwerk
Mittelweg 177
20148 Hamburg
Phone: +49(0)40-41537634
E-Mail: eurocor@blattwerk-kommunikation.de